Following the launch of two oral hypoglycaemic agents (SGLT2-inhibitors) for feline diabetes, Bexacat (bexagliflozin, Elanco) in the US and Senvelgo (Velagliflozin, Boehringer) in the UK and US, BSAVA Congress will be hosting a talk to explore how they…